Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Willem J. Remme
ResearcherPublications, citations & collaboration network
Willem J. Remme is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 230 works, 29,536 citations, an h-index of 48 and an i10-index of 109.
230
Works
29,536
Citations
48
h-index
109
i10-index
IDs:OpenAlex
How has Willem J. Remme's publication output changed over time?
ScholarIQpublication output · 1985–2005
Output grew0% over the shown period — from 1 works in 1985 to 1 in 2005.
1
1
1
2
1
1
2
1
19851986199920002001200220032005
What are the most-cited papers on Willem J. Remme?
ScholarIQmost cited works
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Bertram Pitt, Faı̈ez Zannad, Willem J. Remme, Robert Cody, A Castaigne, A.J. Pérez Pérez, Jolie Palensky, Janet Wittes
New England Journal of Medicine. 19999,145 CitationsOPEN ACCESS
Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
Bertram Pitt, Willem J. Remme, Faı̈ez Zannad, James D. Neaton, Felipe A. Martínez, Barbara Roniker, Richard M. Bittman, Steve Hurley, Jay H. Kleiman, Marjorie Gatlin
New England Journal of Medicine. 20034,932 CitationsOPEN ACCESS
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Bertram Pitt, Faı̈ez Zannad, Willem J. Remme, Robert Cody, A Castaigne, A.J. Pérez Pérez, Jolie Palensky, Janet Wittes
S453935. 20002,937 Citations
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)
Karl Swedberg, John G.F. Cleland, Henry Dargie, Helmut Drexler, Ferenc Folláth, Michel Komajda, Luigi Tavazzi, Otto A. Smiseth, Antonello Gavazzi, Axel Haverich, Arno W. Hoes, Tiny Jaarsma, J Korewicki, Samuel Lévy, Cecilia Linde, J L López-Sendón, Markku S. Nieminen, Luc Piérard, Willem J. Remme
European Heart Journal. 20052,266 CitationsOPEN ACCESS
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial
Philip A. Poole‐Wilson, Karl Swedberg, John G.F. Cleland, Andrea Di Lenarda, Peter Hanrath, Michel Komajda, Jacobus Lubsen, Beatrix Lutiger, Marco Metra, Willem J. Remme, Christian Torp‐Pedersen, Armin Scherhag, Allan M. Skene
The Lancet. 20031,873 CitationsOPEN ACCESS
Related on ScholarIQ
AstraZeneca (United Kingdom)
Institution
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Paper
Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
Paper
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Paper
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)
Paper
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial
Paper